Alain Beck
Senior Director, Biologics CMC Pierre Fabre
Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics programs including dalotuzumab (Merck), telisotuzumab (telisotuzumab vedotin (Emrelis) and adizutecan/ cMet (AbbVie)), h515H7 mAb, lonigutamab (Acelyrin) and lonigutamab ugodotin ADC/ IGF1R, W0180 Vista IO mAb (PF), VERT-002/ cMet (Vertical Bio) and efsudenermin alpha (Esperare Foundation). He is author/ co-author of +270 publications (h-index: 74; +20,000 citations). He has contributed to +300 scientific meetings worldwide as chairman, invited keynote speaker, panellist, moderator, advisor, and/or organizer. He was the winner of 6th WADC (2019). He is member of the MAB Working Party (PhEur) and involved in scientific workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.
Seminars
- Defining CQAs of antibody and bispecific Drug Substance intermediates and ADC Drug Substances and Drug Products
- Exploring the role of cutting-edge analytical strategies based on the use of LC, CE, and MS, either as standalone techniques or in combination
- Evaluating use of tailored analytical methods for comprehensive ADC characterisation and early developability assessment with relevant benchmarks
